203 related articles for article (PubMed ID: 35875064)
1. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
Front Oncol; 2022; 12():851756. PubMed ID: 35875064
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.
Yang X; Yin X; Qu X; Guo G; Zeng Y; Liu W; Jagielski M; Liu Z; Zhou H
J Gastrointest Oncol; 2023 Dec; 14(6):2425-2435. PubMed ID: 38196544
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
Wu Q; Wang Z; Luo Y; Xie X
BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
Sun L; Huang S; Li D; Mao Y; Wang Y; Wu J
Front Oncol; 2021; 11():754881. PubMed ID: 34692541
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
Front Oncol; 2022; 12():917353. PubMed ID: 36226061
[TBL] [Abstract][Full Text] [Related]
8. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.
Li L; Wang T; Wu Z; Li Y; Ma H; Wang L; Lei S; Chen W
Transl Cancer Res; 2023 Nov; 12(11):3034-3044. PubMed ID: 38130300
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
[TBL] [Abstract][Full Text] [Related]
10. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Guo Y; Zhang W; Ying J; Zhang Y; Pan Y; Qiu W; Fan Q; Xu Q; Ma Y; Wang G; Guo J; Su W; Fan S; Tan P; Wang Y; Luo Y; Zhou H; Li J
Eur J Cancer; 2023 Mar; 181():26-37. PubMed ID: 36628898
[TBL] [Abstract][Full Text] [Related]
13. Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.
Dai X; Ding W; He Y; Huang S; Liu Y; Wu T
Front Oncol; 2023; 13():1227644. PubMed ID: 37681031
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
Front Oncol; 2020; 10():594125. PubMed ID: 33282742
[TBL] [Abstract][Full Text] [Related]
15. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
Jiang FE; Zhang HJ; Yu CY; Liu AN
Neoplasma; 2021 Jul; 68(4):861-866. PubMed ID: 33998237
[TBL] [Abstract][Full Text] [Related]
17. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
[No Abstract] [Full Text] [Related]
18. Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study.
Zhou H; Wang Y; Lin Y; Cai W; Li X; He X
Front Oncol; 2021; 11():774445. PubMed ID: 34900725
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
Zou J; Wang Y; Xu J; Li J; Wang T; Zhang Y; Bai Y
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202064
[TBL] [Abstract][Full Text] [Related]
20. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
Front Oncol; 2020; 10():587692. PubMed ID: 33282739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
